MINZOYA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINZOYA (MINZOYA).
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
| Metabolism | Not extensively metabolized; minimal systemic absorption after topical application. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination. |
| Half-life | Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing. |
| Protein binding | Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.8 L/kg, consistent with distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability of 70-80% due to first-pass metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral: 1-2 hours for measurable serum concentrations; clinical effect (reduction in seizure frequency) observed within 2 weeks. |
| Duration of Action | 24 hours with once-daily dosing due to sustained concentrations; steady state achieved in 5-7 days. |
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. No recommended dose. |
| Geriatric use | No specific dose adjustment recommended based on age. Clinical studies included limited number of patients aged ≥65 years; no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINZOYA (MINZOYA).
| Breastfeeding | Misoprostol is excreted into human breast milk; M/P ratio is not established. Peak milk levels occur 1 hour after maternal ingestion. No adverse effects on infants have been reported, but the manufacturer recommends caution. Limited data; avoid prolonged use during breastfeeding. |
| Teratogenic Risk | Minzoya (misoprostol) is contraindicated in pregnancy due to proven teratogenicity. First trimester exposure is associated with Moebius syndrome, limb defects, and fetal death. Second and third trimester use is limited to induction of labor; risk of uterine hyperstimulation and fetal distress. Overall, pregnancy category X. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to zinc pyrithione or any component of the formulation.
| Precautions | For external use only. Avoid contact with eyes. If irritation occurs, discontinue use. May cause local skin reactions such as itching, burning, or erythema. |
Loading safety data…
| Fetal Monitoring | In third trimester use for labor induction: continuous fetal heart rate monitoring and uterine activity monitoring due to risk of hyperstimulation, uterine rupture, and nonreassuring fetal status. For postpartum hemorrhage: monitor uterine tone, blood loss, vital signs and fetal heart rate if fetus still in utero. |
| Fertility Effects | No direct effects on fertility reported in humans. In animal studies, no significant impact on fertility. Misoprostol is used off-label for cervical ripening prior to intrauterine procedures, but no evidence of long-term fertility impairment. |